Company

NurExone Biologic is a publicly traded biopharmaceutical company developing exosome-based regenerative therapies for traumatic central nervous system injuries. The Company’s lead candidate, ExoPTEN, is being developed for acute spinal cord injury and optic nerve damage, with a broader ExoTherapy platform that supports additional therapeutic and commercial applications.

Mission
NurExone’s mission is to develop regenerative exosome-based therapies that address major unmet needs in central nervous system injury and support meaningful functional recovery.

Business Model and Revenue Strategy
NurExone is pursuing a dual-track strategy designed to support both near-term commercial opportunity and long-term therapeutic value creation.

• NurExone is focused on developing ExoPTEN and future loaded-exosome nanodrugs as regulated therapeutic candidates for high-impact medical indications, with potential value creation through clinical development and commercialization.
• In parallel, the Company is advancing near-term commercial opportunities for naïve exosomes through Exo-Top, including potential applications in aesthetics, wellness, and regenerative markets through strategic collaborations.